New Clot-Buster may be safer for stroke patients
NCT ID NCT07519889
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study will compare the safety of two clot-dissolving drugs, rhTNK-tPA and rt-PA, in 4500 adults having an acute ischemic stroke. Researchers will track how often each drug causes serious bleeding in the brain within 36 hours. The goal is to see if the newer drug, rhTNK-tPA, is safer in real-world use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- clot-busting drugs (rhTNK-tPA and rt-PA)
- What this could lead to
- If rhTNK-tPA proves safer than rt-PA, it could become a preferred treatment for acute ischemic stroke, reducing the risk of brain bleeding.
- What could go wrong
- This is an observational study, not a randomized trial, so results may be influenced by patient differences. Both drugs carry a risk of serious bleeding in the brain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could muscle loss predict stroke recovery?
- Can a drug boost brain recovery after stroke?
- Can a blood Clot's inflammation predict stroke recovery?
- Can a new infusion drug boost stroke recovery?
- Can removing clots from tiny brain arteries boost stroke recovery?
- Could vague stroke symptoms delay lifesaving treatment?